The high cost of brand‐name medications contributes significantly to the utilization of generic versions of drugs in place of their brand‐name counterparts. Since generic and brand‐name medications share the identical chemical entity, it is generally anticipated by insurance payors, providers, and patients that the efficacy and side effect profiles of the two will be very similar. The Food and Drug Administration requires evidence of bioequivalence, showing similar concentration‐time profiles within acceptable predetermined limits, as the primary determinant for decision making in approving generic drugs.